Targeted Therapy
Approved for: NSCLC
Biomarker: EGFR Exon20 Insertion
Mobocertinib (EXKIVITY) is the first oral therapy specifically designed for patients with EGFR Exon20 insertion+ NSCLC
Mobocertinib (EXKIVITY) is the first oral therapy specifically designed for patients with EGFR Exon20 insertion+ NSCLC